IONS - Ionis Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
68.56
-0.68 (-0.98%)
At close: 4:00PM EDT

68.56 0.00 (0.00%)
Pre-Market: 8:58AM EDT

Stock chart is not supported by your current browser
Previous Close69.24
Open69.32
Bid68.00 x 800
Ask73.87 x 900
Day's Range67.50 - 69.66
52 Week Range40.91 - 86.58
Volume1,236,153
Avg. Volume1,386,508
Market Cap9.621B
Beta (3Y Monthly)1.82
PE Ratio (TTM)25.83
EPS (TTM)2.65
Earnings DateAug 5, 2019 - Aug 9, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est69.07
Trade prices are not sourced from all markets
  • Thomson Reuters StreetEvents2 days ago

    Edited Transcript of IONS earnings conference call or presentation 9-May-19 3:30pm GMT

    Q1 2019 Ionis Pharmaceuticals Inc Earnings Call

  • Credit Suisse Absolutely Is Right to Double Down on Pfizer Stock
    InvestorPlace3 days ago

    Credit Suisse Absolutely Is Right to Double Down on Pfizer Stock

    After upgrading Pfizer (NYSE:PFE) to "Outperform" in January and raising its price target on Pfizer stock to $48 in May, one would think there's nothing else Credit Suisse could so to bolster its bullish case, but there is.Source: Kojach Via FlickrFollowing a meeting with the pharmaceutical giant's top brass just a few days ago, on Thursday, Credit Suisse labeled PFE stock a "top pick." It was apparently one heck of a meeting.The specifics prompting the accolade weren't made crystal clear, though Credit Suisse did note that the company's prospects for new products was compelling. Translation: Whatever stoked Credit Suisse's fires is likely to be in the company's late-stage pipeline, which is admittedly more exciting than it has been in a long while.InvestorPlace - Stock Market News, Stock Advice & Trading Tips * 7 High-Yield REITs to Buy (Even When the Market Tanks) A Brief Look at PfizerIt's not a story that needs a great deal of retelling. It was an unstoppable powerhouse when it had full patent protection of its erectile dysfunction drug Viagra and faced little competition. But, seeing the writing on the wall, the drugmaker allowed Teva Pharmaceutical Industries (NYSE:TEVA) to begin selling a generic version of the drug in 2017. In the meantime, consumer interest in ED drugs has broadly waned.Pfizer is about to lose ground with blockbuster neuropathic pain drug Lyrica too, which lost patent protection last year, threatening to quickly cut its $5 billion in annual sales in half once generic alternatives become available.It's the same story that plays out over and over within the pharmaceutical industry; these organizations must constantly replenish their portfolios with patent-protected drugs, or risk losing ground.It's something Pfizer hasn't done especially well in recent years.Although Pfizer stock has made reliable if choppy progress since turning around with all other stocks in 2009, revenue growth hasn't been overwhelming. The $53.9 billion in sales generated over the course of the past four reported quarters was not remarkable better than the $52.7 billion figure from a year earlier."Pfizer has been working through a dark period with extensive patent expirations," Credit Suisse analyst Vamil Divan said in late January. "That period is now nearing an end." Solid PipelineWhat Pfizer told Credit Suisse at the meeting remains veiled, though when Divan upgraded Pfizer stock early this year he explicitly noted opportunities for several cancer and autoimmune disease drugs along with vaccinations.Two of the drugs Divan had in mind are Vyndaqel and Vyndamax (though they're actually different doses of the same molecule), which combats the buildup for amyloid in the heart.Alnylam Pharmaceuticals (NASDAQ:ALNY) and Ionis Pharmaceuticals (NASDAQ:IONS) already make similar rival drugs, but their versions are considerably more expensive. Divan foresees peak sales of $2 billion for Vyndaqel, but is willing to entertain a number "significantly larger than that if Pfizer is able to commercialize it successfully."Pfizer has also partnered with Eli Lilly (NYSE:LLY) on the development of a non-opioid arthritis treatment called tanezumab, another one of the 15 game-changing drugs Pfizer believes could be brought to the market within the next five years.Some analysts are looking for modest peak sales of around $500 million, although Cantor Fitzgerald analyst Louise Chen thinks tanezumab could prove to a multi-billion dollar opportunity to replace a significant piece of the existing opioid market.In the meantime, Pfizer aims to widen the uses of already-marketable drugs like Ibrance, Eliquis, and Xeljanz.Ibrance has already become something of a wonder drug. Already approved as a therapy for multiple forms of breast cancer and generating revenue of $4.1 billion last year, expanded labeling could translate into peak annualized revenue of $8 billion before the treatment hits its ceiling.Eliquis (or Apixaban) for blood clots, co-marketed with Bristol-Myers Squibb (NYSE:BMY), and arthritis/ulcerative colitis therapy Xeljanz generated nearly $3.5 billion and more than $1.7 billion worth of revenue for Pfizer last year, respectively, yet both are also in trials for new uses after having proven they're safe and effective.All told, Pfizer's got 23 phase 3 trials underway right now. All of them look promising; most of them appear to have blockbuster potential. Looking Ahead for Pfizer StockIt was self-serving to be sure when CEO Albert Bourla proclaimed in January that Pfizer is sitting on its "greatest pipeline ever."But that doesn't mean he's wrong.Granted, the deterioration of Pfizer stock since December's peak (PFE stock been performing completely contrary to the market for months) says investors don't exactly believe Bourla. The crowd has understandably become a "show me first" mob, willing to wait on the sidelines for proof that the pipeline can do all the company suggests it can do.Credit Suisse's Divan may have the right idea though. The time to step into a great prospect is when its stock is down because the majority of investors aren't convinced and analysts are collectively lukewarm because they're unable to see more than a few months down the road.That's certainly Pfizer stock right now.As of this writing, James Brumley did not hold a position in any of the aforementioned securities. You can learn more about James at his site, jamesbrumley.com, or follow him on Twitter, at @jbrumley. More From InvestorPlace * 4 Top American Penny Pot Stocks (Buy Before June 21) * 7 High-Yield REITs to Buy (Even When the Market Tanks) * 5 Great Blue-Chip Stocks to Buy Today * 7 Tech Stocks to Buy That Are Also Perfect for Retirement Compare Brokers The post Credit Suisse Absolutely Is Right to Double Down on Pfizer Stock appeared first on InvestorPlace.

  • 7 A-Rated Healthcare Stocks for Industry Expansion
    InvestorPlace3 days ago

    7 A-Rated Healthcare Stocks for Industry Expansion

    According to the Centers for Medicare and Medicaid Services, healthcare spending will rise 5.5% annually through 2026, when that spending will represent 20% of the country's GDP; a boon for healthcare stocks.To put this in perspective, the U.S. defense budget is about 18% of the entire U.S. budget and we outspend every other nation on this planet in defense spending by a significant margin.The U.S. healthcare system is being debated again and may well be a significant issue in the upcoming presidential election.InvestorPlace - Stock Market News, Stock Advice & Trading TipsBut the reality is, the U.S. population is getting older and that means more chronic diseases begin to take their toll. Also, older people tend to take up a larger portion of healthcare costs as their health begins to fail. * 7 High-Yield REITs to Buy (Even When the Market Tanks) That means there will be an unstoppable growth trend in place for healthcare companies. The A-rated healthcare stocks I feature here are well placed to take advantage of this trend. And they're small enough that their growth will outpace their larger competitors and may make them interesting takeover targets.Source: Flickr Masimo (MASI)Masimo Corp (NASDAQ:MASI) is the perfect example of how technology is transforming healthcare.Once, heading the doctors or the hospital was a regular occurrence for patients with chronic issues like heart disease or diabetes. But now, monitoring technologies, where patients can wear a device that essentially tracks their functions and the data can either be downloaded remotely or by the patient and sent to the doctor, are becoming increasingly common.And MASI is one of the leaders in the field. It is also one of the two top players in the pulse oximetry sector. These are devices that check the oxygen saturation level a person's blood. Hospitals use these a great deal and generally the contracts run on a five-year basis, so income is steady and once they're in place it's unlikely the hospitals will switch over to a new type of unit, so there are solid competitive moats.MASI is up almost 44% in the past 12 months, and much of that has come in 2019. This is the kind of company that can grow with the market regardless of what U.S. healthcare ends up looking like.Source: Shutterstock Ionis Pharmaceuticals (IONS)Ionis Pharmaceuticals (NASDAQ:IONS) was founded by leading biotech scientists to expand the use of antisense therapy. It's a new form of treatment that is at the cutting edge of science medicine.Basically, if you can find a genetic marker for a disease, you can synthesize a strand of RNA that can render that gene inactive, so it doesn't reproduce. The potential uses extend to cancers, heart disease, diabetes, asthma, arthritis … the list goes on. * 6 Chinese Stocks That Could Pop On a Trade Deal This technology has the potential to help both rare and common maladies, many of which don't have current effective treatments.IONS is already partnered with a number of larger pharmaceutical firms and is up 55% in the past year, with plenty of headroom left.Source: Shutterstock Osiris Therapeutics (OSIR)Osiris Therapeutics (NASDAQ:OSIR) has a market cap around $650 million, so it's in that perfect spot where it has the potential for big growth on its own, or it could be a target for takeover at a nice premium for a larger pharma looking for a unique product line.OSIR specializes in regenerative medicine products. What that means is, it uses stem cells to build medicines that help everything from wound healing to bone marrow graft acceptance. It's a unique space that has significant possibilities now and for the future.It currently has five products on the market that are focused on wound healing, ligament repairs and surgical wraps on tissues. All promote better healing outcomes with less infections than traditional methods.Last quarter it sold the rights to one of its top stem cell drug for $100 million, so it's work is being recognized. OSIR stock is up 141% for the year and 40% in 2019.Source: Shutterstock Ensign Group (ENSG)Ensign Group (NASDAQ:ENSG) specializes in post-acute care staffing for a wide variety of facilities that would need these services. Some of the most obvious would be assisted living facilities, home health care, rehab facilities and hospice. It manages 250 companies in more than 12 states, around the U.S.This is precisely the sort of sector that will be in huge demand in coming years. While all the technology and new drugs are great, there will still need to be qualified people helping support the patients as they recover and attempt to maintain active lifestyles. * 10 Retirement Stocks That Won't Wilt in a Bear Market It continues to expand its base in California, where the company is headquartered, having just bought another company in Southern California. But its operations beyond the state show that it has what it takes to expand its model where the most opportunity is.Up 59% in the past year, its size makes it a potential takeover target or a big grower on its own.Source: Shutterstock Genomic Health (GHDX)Genomic Health (NASDAQ:GHDX) specializes in genomic diagnostic testing, specifically for cancer. The testing allows for patients and doctors to create individualized treatment strategies for patients.This is important because it means patients get the treatment they need -- they're not over-treated or under-treated. And that is good for the whole healthcare system as well as the patients.Again, this kind of diagnostic tool will be something that insurers, hospitals and patients can get behind since it allows care to better suited to each patient with the goal of lowering costs and improving outcomes.The stock is up over 38% in the past year and it's still going strong.Source: Shutterstock National Research Corp (NRC)National Research (NASDAQ:NRC) is all about delivering all the best possible outcomes for patients with their healthcare providers. NRC sees the current and future healthcare sector as patient-driven, and that is not the traditional model.The patient wasn't much more than a bundle of symptoms that were inserted into the healthcare machines to get repaired and sent back out into the world before. Now, it's about creating an experience that not only serves the patient better, but is able to deliver better outcomes and fewer return visits. It's looking at numbers that view the system more holistically.And NRC provides those numbers from its research. * 7 Cloud Stocks to Buy on Overcast Days While it has been around since 1981, NRC is just coming into its own. And it would be a great takeover target for one of the big healthcare insurers or a large hospital chain.Up 26% in the past year, NRC also delivers a nearly a 2% dividend.Source: Shutterstock AngioDynamics (NASDAQ:ANGO) is a medical device company that specializes in equipment that's used for vascular access, surgery, vascular disease and oncology. It actually made a new acquisition earlier this year to increase its oncology suite of products.Specialty medical device makers are in particular demand globally, since the good ones tend to get most of the business. Medicine is a very conservative practice and tested and true is much more preferable to new and interesting.And generally that's the view from hospitals, insurers and patients. It takes years to put new equipment in place and generally the new equipment is from a trusted equipment maker and not the kid on the block. Having been around since 1988, ANGO fits that bill.Although its global potential looks huge as China looks to upgrade its entire healthcare system, it's been volatile over the last year and relatively flat (actually down .3%). Most of the volatility is trade war related and that can't last forever.Louis Navellier is a renowned growth investor. He is the editor of four investing newsletters: Growth Investor, Breakthrough Stocks, Accelerated Profits and Platinum Growth. His most popular service, Growth Investor, has a track record of beating the market 3:1 over the last 14 years. He uses a combination of quantitative and fundamental analysis to identify market-beating stocks. Mr. Navellier has made his proven formula accessible to investors via his free, online stock rating tool, PortfolioGrader.com. Louis Navellier may hold some of the aforementioned securities in one or more of his newsletters. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 5 Low-Priced Tech Stocks With Great Potential * 9 Stocks That Would Be Hurt By a Mexico/U.S. Border Closure * The Era of Car Ownership Is Over. And These 4 Charts Prove It Compare Brokers The post 7 A-Rated Healthcare Stocks for Industry Expansion appeared first on InvestorPlace.

  • GlobeNewswire9 days ago

    Biogen’s SPINRAZA® (nusinersen) Receives Positive Recommendation from NICE for Funding in the United Kingdom for the Treatment of Infants, Children and Adults with Spinal Muscular Atrophy

    Biogen Inc. (BIIB) today announced that The National Institute for Health and Care Excellence (NICE) in the United Kingdom has recommended funding for SPINRAZA (nusinersen) on the National Health Service (NHS). The positive recommendation is for the treatment of infants, children and adults with 5q spinal muscular atrophy (SMA), including pre-symptomatic and symptomatic SMA Types 1, 2 and 3.

  • Ionis Pharmaceuticals Is 40% of the Way There
    Motley Fool9 days ago

    Ionis Pharmaceuticals Is 40% of the Way There

    A large licensing payment from one of the biotech's partners drives revenue growth.

  • Markit9 days ago

    See what the IHS Markit Score report has to say about Ionis Pharmaceuticals Inc.

    Ionis Pharmaceuticals Inc NASDAQ/NGS:IONSView full report here! Summary * Bearish sentiment is moderate and increasing Bearish sentimentShort interest | NeutralShort interest is moderate for IONS with between 5 and 10% of shares outstanding currently on loan. This represents an increase in short interest as investors who seek to profit from falling equity prices added to their short positions on May 10. Money flowETF/Index ownership | NeutralETF activity is neutral. The net inflows of $4.99 billion over the last one-month into ETFs that hold IONS are not among the highest of the last year and have been slowing. Economic sentimentPMI by IHS Markit | NeutralAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • Ionis Pharmaceuticals, Inc. (IONS) Q1 2019 Earnings Call Transcript
    Motley Fool13 days ago

    Ionis Pharmaceuticals, Inc. (IONS) Q1 2019 Earnings Call Transcript

    IONS earnings call for the period ending March 31, 2019.

  • Highly-Rated Biotech Post 106% Sales Growth In Profitable First Quarter
    Investor's Business Daily14 days ago

    Highly-Rated Biotech Post 106% Sales Growth In Profitable First Quarter

    Ionis earnings of 62 cents a share and $288 million in sales beat first-quarter views on Thursday. On an adjusted basis, earnings were 89 cents per share. Ionis stock slid at the close.

  • Ionis Pharmaceuticals (IONS) Beats Q1 Earnings and Revenue Estimates
    Zacks14 days ago

    Ionis Pharmaceuticals (IONS) Beats Q1 Earnings and Revenue Estimates

    Ionis Pharmaceuticals (IONS) delivered earnings and revenue surprises of 113.95% and 3.27%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Press14 days ago

    Ionis Pharmaceuticals: 1Q Earnings Snapshot

    The Carlsbad, California-based company said it had net income of 62 cents per share. Earnings, adjusted for non-recurring costs, came to 92 cents per share. The results topped Wall Street expectations. ...

  • Ionis reports first quarter 2019 financial results
    PR Newswire14 days ago

    Ionis reports first quarter 2019 financial results

    Revenues more than doubled compared to 2018, resulting in net income of $84 million Nearly $300 million in revenues driven by $150 million license fee from Novartis and growing commercial revenues Conference ...

  • GlobeNewswire15 days ago

    Akcea Reports Financial Results and Highlights for First Quarter 2019

    Achieved First Quarter 2019 TEGSEDI® (inotersen) Global Net Product Revenues of $7 Million  Novartis exercised its option to license AKCEA-APO(a)-LRx Received marketing.

  • Drug/Biotech Stock Q1 Earnings on May 9: IONS, XLRN & More
    Zacks15 days ago

    Drug/Biotech Stock Q1 Earnings on May 9: IONS, XLRN & More

    Five drug/biotech stocks are scheduled to release their first-quarter results on May 9. Let's take a look at how these companies are poised ahead of their earnings release.

  • GlobeNewswire16 days ago

    New Long-Term TEGSEDI Safety and Efficacy Data Featured as an Oral Presentation at 2019 American Academy of Neurology Annual Meeting (AAN)

    Akcea Therapeutics, Inc. (AKCA), an affiliate of Ionis Pharmaceuticals, Inc., and Ionis Pharmaceuticals, Inc. (IONS) today announced new long-term, open-label extension (OLE) data from the NEURO-TTR study of TEGSEDI® (inotersen) in patients with hereditary ATTR amyloidosis (hATTR) with polyneuropathy. The data was highlighted as an oral presentation at the 2019 American Academy of Neurology (AAN) Annual Meeting in Philadelphia.

  • GlobeNewswire16 days ago

    Akcea and Ionis Announce Approval of WAYLIVRA® (volanesorsen) in the European Union

    Akcea Therapeutics, Inc. (AKCA), an affiliate of Ionis Pharmaceuticals, Inc., and Ionis Pharmaceuticals, Inc. (IONS), announced today that WAYLIVRA has received conditional marketing authorization from the European Commission (EC) as an adjunct to diet in adult patients with genetically confirmed FCS and at high risk for pancreatitis, in whom response to diet and triglyceride lowering therapy has been inadequate. This authorization follows the positive opinion recommending approval provided by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA).

  • How Dow Jones' Pfizer Could Take On New Drugs From 2 Biotech Stocks
    Investor's Business Daily17 days ago

    How Dow Jones' Pfizer Could Take On New Drugs From 2 Biotech Stocks

    Dow Jones component Pfizer gained approval Monday for a drug that treats a rare heart disease — potentially rivaling new drugs from Alnylam Pharmaceuticals and Ionis Pharmaceuticals.

  • Ionis launches new corporate brand that reflects company's industry-leading innovation and unique culture of saying "yes" to patients
    PR Newswire17 days ago

    Ionis launches new corporate brand that reflects company's industry-leading innovation and unique culture of saying "yes" to patients

    CARLSBAD, Calif., May 6, 2019 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (IONS) today unveiled its new corporate brand in a campaign inspired by its unique culture and history of developing transformative therapies for seemingly untreatable diseases. The brand refresh comes as Ionis celebrates its 30th anniversary. "Our new brand is a bold, fresh expression of what we've lived and breathed at Ionis for 30 years – an unwavering passion for discovering and developing novel medicines and a steadfast commitment to saying yes to the patients who depend on us to create them," said Stanley T. Crooke, M.D., Ph.D., Ionis' founder, chairman and chief executive officer.

  • Ionis Pharmaceuticals (IONS) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
    Zacks21 days ago

    Ionis Pharmaceuticals (IONS) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

    Ionis Pharmaceuticals (IONS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • GlobeNewswire21 days ago

    Akcea Announces Upcoming Data Presentations at the 2019 American Academy of Neurology Meeting (AAN.19)

    Akcea Therapeutics, Inc. (AKCA), an affiliate of Ionis Pharmaceuticals, Inc. (IONS), today announced that data from the NEURO-TTR open-label extension study and the clinical impact of TEGSEDI on patients living with hereditary transthyretin amyloidosis (hATTR) will be presented at the American Academy of Neurology 71st Annual Meeting (AAN) in Philadelphia, May 4-10, 2019.

  • Zacks22 days ago

    S&P Ends a Strong April with 3rd Straight Record Close

    S&P; Ends a Strong April with 3rd Straight Record Close

  • PR Newswire22 days ago

    Positive clinical data at AAN 2019 reinforces Ionis' commitment to delivering life-changing medicines to patients with neurological diseases

    Twelve presentations highlighting transformational medicines for SMA, hATTR, Huntington's disease, ALS, prion disease and others Updates on RG6042 (IONIS-HTTRx) and tofersen (IONIS-SOD1Rx), two of at least ...

  • Ionis Pharmaceuticals (IONS) Earnings Expected to Grow: What to Know Ahead of Q1 Release
    Zacks27 days ago

    Ionis Pharmaceuticals (IONS) Earnings Expected to Grow: What to Know Ahead of Q1 Release

    Ionis Pharmaceuticals (IONS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • Biogen Looks to 23 Clinical Programs for Growth
    Motley Fool28 days ago

    Biogen Looks to 23 Clinical Programs for Growth

    First-quarter sales were up 11%, but future growth is less certain.

  • PR Newswire28 days ago

    Ionis Pharmaceuticals to hold first quarter 2019 financial results webcast

    CARLSBAD, Calif., April 25, 2019 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (IONS) announced today that it will host a live webcast on Thursday, May 9th at 11:30 a.m. Eastern Time to discuss its first quarter 2019 financial results and report on pipeline and business progress. As the leader in RNA-targeted drug discovery and development, Ionis has created an efficient, broadly applicable, drug discovery platform called antisense technology that can treat diseases where no other therapeutic approaches have proven effective.

  • Zacks29 days ago

    Solid Earnings Boost S&P, NASDAQ to New Closing Highs

    Solid Earnings Boost S&P;, NASDAQ to New Closing Highs